ストックスクリーナーアプリを入手
2.57
11.73%
0.31
アフターアワーズ：
2.58
0.01
+0.39%
前日終値:
$2.26
開ける：
$2.3
24時間の取引高:
321.29K
Relative Volume:
0.57
時価総額：
$2.62M
収益：
-
当期純損益:
$-6.64M
株価収益率:
-0.1422
EPS:
-18.0702
ネットキャッシュフロー:
$-5.60M
1週間 パフォーマンス:
+6.86%
1か月 パフォーマンス:
-68.90%
6か月 パフォーマンス:
-95.93%
1年 パフォーマンス:
-99.35%
1日の値動き範囲:
$2.28
$2.698
1週間の範囲:
$2.10
$2.698
52週間の値動き範囲:
$2.10
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
2.57 | 2.30M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc (CMND) 最新ニュース
Clearmind Medicine Advances Cmnd-100 Phase I/Ii Clinical Trial to Next Parts - marketscreener.com
Clearmind Medicine stock gains on Johns Hopkins trial approval By Investing.com - Investing.com Canada
Clearmind Medicine stock gains on Johns Hopkins trial approval - Investing.com
Clearmind receives Johns Hopkins IRB approval for trial parts - Investing.com
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts - The Manila Times
Clearmind receives Johns Hopkins IRB approval for trial parts By Investing.com - Investing.com Canada
Clearmind Medicine Inc. Receives IRB Approval for Phase I/II Clinical Trial of CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Cash from financing activities of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Net income before discontinued operations of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Clearmind Medicine Inc. Balance Sheet – LS:A427B1 - TradingView
Price to earnings ratio of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Clearmind Medicine Inc. Dividends – LS:A427B1 - TradingView
Clearmind Medicine Inc. Earnings and Revenue – LS:A427B1 - TradingView
CMND News | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Will Clearmind Medicine (NASDAQ:CMND) Spend Its Cash Wisely? - Sahm
Clearmind Medicine to implement 1-for-10 reverse share split - MSN
Clearmind Medicine stock tumbles on reverse share split plan By Investing.com - Investing.com Nigeria
Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings - Benzinga
Clearmind Medicine stock tumbles on reverse share split plan - Investing.com
Clearmind Medicine to implement 1-for-10 reverse stock split By Investing.com - Investing.com South Africa
they’re doing it for the hell of it. - Moomoo
Clearmind Medicine to implement 1-for-10 reverse stock split - Investing.com
Clearmind Medicine Inc. Announces 1-for-10 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative
Clearmind Medicine announces 1-for-10 reverse share split - marketscreener.com
Clearmind Medicine Announces 1-for-10 Reverse Share Split - The Manila Times
Clearmind Medicine Announces 1-For-10 Reverse Share Split - TradingView
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
$Clearmind Medicine (CMND.US)$[Lol][Lol][Lol] - Moomoo
Clearmind signs research deal to study obesity drug combination By Investing.com - Investing.com Australia
Clearmind signs research deal to study obesity drug combination - Investing.com UK
Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND) - Yahoo Finance
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications - The Manila Times
Clearmind Medicine Inc. And Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Sign Agreement To Examine MEAI In Combination And Sequencing With Tirzepatide - marketscreener.com
Clearmind Medicine CEO Dr. Adi Zuloff-Shani Participates in Psychedelic Medicine Coalition Federal Policy Summit - Quiver Quantitative
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. - The Manila Times
Number of shareholders of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
TradingKey - TradingKey
Clearmind doses two more patients in alcohol disorder trial - Investing.com UK
Clearmind Medicine Treats 20 Participants in CMND-100 Alcohol Use Disorder Trial - geneonline.com
20 patients treated in Clearmind (Nasdaq: CMND) Phase I/IIa AUD study - Stock Titan
Clearmind doses two more patients in alcohol disorder trial By Investing.com - Investing.com Nigeria
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - The Manila Times
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing ... - Caledonian Record
Novel non-hallucinogenic alcohol use disorder drug reaches 20 patients - Stock Titan
Clearmind Medicine announces "Inside MEAI" webinar featuring new insights from CMND-100 psychedelic clinical trial - marketscreener.com
Clearmind Medicine Inc (CMND) 財務データ
収益
当期純利益
現金流量
EPS
1.49%
0.12%
大文字化:
|
ボリューム (24 時間):